文献速递认知障碍与痴呆

原发性年龄相关tau蛋白病症状性与无症状性患者的比较

Comparison of symptomatic and asymptomatic persons with primary age-related tauopathy.
PubMed 文献 · Neurology · 2017-09-15

本研究基于美国国家阿尔茨海默病协调中心数据库,纳入377例尸检确诊的PART definite(n=170)或淀粉样斑块稀疏(n=207)患者,比较其临床与神经病理特征。结果发现PART definite患者较淀粉样斑块稀疏者更少出现症状(58% vs 80%,p<0.001),且其症状独立预测因素包括抑郁、Braak分期和卒中史。结论支持PART是一种不依赖淀粉样蛋白的阿尔茨海默病样颞叶tau蛋白病。

要点

  • PART definite患者症状出现率低于淀粉样斑块稀疏者(58% vs 80%)。
  • PART患者症状独立预测因素:抑郁、Braak分期、卒中史。
  • 淀粉样斑块稀疏者症状预测因素:教育、Braak分期、淀粉样血管病。

核心结论

  • PART患者具有不依赖淀粉样蛋白的阿尔茨海默病样颞叶tau蛋白病特征。

研究设计与样本

  • 基于国家阿尔茨海默病协调中心数据库的临床病理研究,纳入377例尸检病例(PART definite 170例,淀粉样斑块稀疏207例),均在死亡前1年内接受临床检查。

主要发现

  • PART definite患者Braak V或VI期比例低于淀粉样斑块稀疏者(4% vs 28%,p<0.001)。
  • PART definite患者症状出现率低于淀粉样斑块稀疏者(58% vs 80%,p<0.001)。
  • PART definite组症状独立预测因素:抑郁(aOR 4.20,95%CI 2.15-8.19)、Braak分期(aOR 1.42,95%CI 1.04-1.95)、卒中史(aOR 8.09,95%CI 2.63-24.82)。
  • 淀粉样斑块稀疏组症状独立预测因素:教育(aOR 0.80,95%CI 0.65-0.99)、Braak分期(aOR 1.91,95%CI 1.07-3.43)、淀粉样血管病(aOR 2.75,95%CI 1.14-6.64)。

临床怎么用

  • 对PART患者应评估抑郁、卒中史及Braak分期以识别症状风险。
  • 淀粉样斑块稀疏者需关注教育水平、Braak分期及淀粉样血管病对症状的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To conduct a clinicopathologic study to characterize clinical and neuropathologic features associated with cognitive impairment in participants with no neuritic amyloid plaques (primary age-related tauopathy [PART] definite) and sparse neuritic plaques (amyloid sparse). METHODS: Using the National Alzheimer's Coordinating Center database, we identified 377 individuals who were PART definite (n = 170) or amyloid sparse (n = 207), clinically examined within 1 year of death, and autopsied at 1 of 26 National Institute on Aging-funded Alzheimer's Disease Centers. Factors associated with the odds of being symptomatic (global Clinical Dementia Rating [CDR] score >0) were identified with multivariable logistic regression. RESULTS: PART-definite participants less often had a high Braak neurofibrillary tangle stage V or VI (4%) compared to amyloid sparse participants (28%, p < 0.001). Of the PART-definite participants, 98 were symptomatic and 72 asymptomatic according to their global CDR scores. PART-definite participants were less often symptomatic (58%) compared with amyloid sparse participants (80%, p < 0.001). Within the PART-definite group, independent predictors of symptomatic status included depression (adjusted odds ratio [aOR] 4.20, 95% confidence interval [CI] 2.15-8.19), Braak stage (aOR 1.42, 95% CI 1.04-1.95), and history of stroke (aOR 8.09, 95% CI 2.63-24.82). Within the amyloid sparse group, independent predictors of symptomatic status included education (aOR 0.80, 95% CI 0.65-0.99), Braak stage (aOR 1.91, 95% CI 1.07-3.43), and amyloid angiopathy (aOR 2.75, 95% CI 1.14-6.64). CONCLUSIONS: These findings support the hypothesis that participants with PART have an amyloid-independent dementing Alzheimer disease-like temporal lobe tauopathy.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Besser LM, Crary JF, Mock C, et al. Comparison of symptomatic and asymptomatic persons with primary age-related tauopathy. Neurology. 2017. PMID: 28916532. doi:10.1212/WNL.0000000000004521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。